SOURCE: Maybach Financial Group

Maybach Financial Group

October 19, 2007 13:39 ET

Post Conference and Q3 Focus on CytRx Corporation, Oscient Pharmaceuticals Corporation, and Santarus, Inc.

Awareness Brings Added Value

NOTE TO EDITORS: This Is an Investment Opinion Issued by The Maybach Financial Group

GRANDE BAY, MAURITIUS--(Marketwire - October 19, 2007) - Comments made in this release are those of Maybach Financial Group and any questions or comments should be directed to the contact information located at the bottom of this release.

Maybach Financial Group is a syndicate of financial analysts, with a core group representing over 250 years of total investing experience. Our focus is to give investors the financial advantage necessary to sustain profit all markets. This week, to gauge the outcome of the markets, we are focusing on CytRx Corporation (NASDAQ: CYTR), Oscient Pharmaceuticals Corporation (NASDAQ: OSCI), and Santarus, Inc. (NASDAQ: SNTS). For the full report and a complimentary subscription to the Maybach service, visit

The Maybach Financial Group ( will be researching the above-mentioned companies to determine their chances of a turnaround opportunity for investors.

With Q3 earnings and major biotech conferences being held recently, many companies within the sector have seen a growth in awareness.

CytRx Corporation (NASDAQ: CYTR) hit a day-high of $3.78 in early trades. Often, a company's lack of exposure in the investment world can lead to a downfall in their overall value. It has become apparent that CytRX Corp understands that and announced they are going to present at numerous conferences.

Pharmaceutical and life sciences companies are among the most analysed and evaluated organisations in business today. Over the course of this decade, scientists are predicting a dramatic change over the innovation and use of drugs. The time is now for these companies to gain exposure and take advantage of the biotech market now.

In the future, the approach that companies pursue will depend in large measure upon their individual goals.

Oscient Pharmaceuticals Corporation (NASDAQ: OSCI) declared on 10 October its preliminary revenue results for the third quarter of 2007. Today, they hit a day-high of $2.18 up over 14.73% midway through the trading day. They also just recently presented at the Natixis Bleichroeder Hidden Gems Conference which appears to be having an effect on their recent share value.

For a limited time only, gain access to Maybach and our reports free of charge with no credit card or payment information required. Visit for your free subscription.

Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, recently announced that it will release third quarter 2007 financial results after market close on Thursday, November 1, 2007. Today they hit a day-high of $2.35, up over 8% in mid-day trading -- potentially due to the anticipation of their Q3 results. They also recently presented late last month at the UBS 2007 Global Life Sciences Conference.

In the battle for supremacy with big shot companies such as Pfizer, the juniors involved within this particular sector have a lot of leverage as these big companies continue to invest and scan for new patents, licenses, and drugs.

It's a tough world out there for big pharmaceuticals, but it helps the junior world move forward.

Something to bear in mind is that only a small fraction of the public could name any company that develops vaccines to prevent an epidemic (4%), provides medicines or medical equipment in case of a major disaster (7%), or contributes to patient assistance programs (14%).

Despite a new loyal following for new age ideas and a "greener" life using organics and natural cures, the view on innovative drugs remains strong. If pharmaceutical companies could raise awareness of their philanthropic actions, they would undoubtedly make gains in countering negative feelings toward the sector.

For a limited time, receive a complimentary subscription to the Maybach service by visiting to receive two Special Reports with information on how to not only combat the markets.

Maybach Financial (Maybach) is not a registered broker dealer or a registered investment advisor. No information accessed through the Maybach Web site or this release constitutes a recommendation to buy, sell or hold any security in any jurisdiction. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. There is no financial relationship that exists between the issuer of this release and the company whose stock is mentioned in the release. Please view the disclaimer at

Statements made in this release may include forward-looking statements and projections, made in reliance on the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Maybach has made every reasonable effort to ensure that the information and assumptions on which these statements and projections are based are current, reasonable, and complete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release. Maybach makes these statements and projections in good faith, neither Maybach nor its management can guarantee that the transactions will be consummated or that anticipated future results will be achieved. All material herein was based upon information believed to be reliable. The information contained herein is not guaranteed by Maybach to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Maybach assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by Maybach, whether as a result of new information, future events, or otherwise.

Contact Information

    The Maybach Financial Group
    Toll Free: 1-800-344-4888
    Email: Email Contact